Amyloid-β Peptides Activate α 1 -Adrenergic Cardiovascular Receptors
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Alzheimer disease features amyloid-β (Aβ) peptide deposition in brain and blood vessels and is associated with hypertension. Aβ peptide can cause vasoconstriction and endothelial dysfunction. We observed that Aβ peptides exert a chronotropic effect in neonatal cardiomyocytes, similar to α 1 -adrenergic receptor autoantibodies that we described earlier. Recently, it was shown that α 1 -adrenergic receptor could impair blood–brain flow. We hypothesized that Aβ peptides might elicit a signal transduction pathway in vascular cells, induced by α 1 -adrenergic receptor activation. Aβ (25–35) and Aβ (10–35) induced a positive chronotropic effect in the cardiac contraction assay (28.75±1.15 and 29.40±0.98 bpm), which was attenuated by α 1 -adrenergic receptor blockers (urapidil, 1.53±1.17 bpm; prazosin, 0.30±0.96 bpm). Both Aβ peptides induced an intracellular calcium release in vascular smooth muscle cells. Chronotropic activity and calcium response elicited by Aβ (25–35) were blocked with peptides corresponding to the first extracellular loop of the α 1 -adrenergic receptor. We observed an induction of extracellular-regulated kinase 1/2 phosphorylation by Aβ (25–35) in Chinese hamster ovary cells overexpressing α 1 -adrenergic receptor, vascular smooth muscle cells, and cardiomyocytes. We generated an activation-state–sensitive α 1 -adrenergic receptor antibody and visualized activation of the α 1 -adrenergic receptor by Aβ peptide. Aβ (25–35) induced vasoconstriction of mouse aortic rings and in coronary arteries in Langendorff-perfused rat hearts that resulted in decreased coronary flow. Both effects could be reversed by α 1 -adrenergic receptor blockade. Our data are relevant to the association between Alzheimer disease and hypertension. They may explain impairment of vascular responses by Aβ and could have therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213
β-Amyloid-mediated vasoactivity and vascular endothelial damage
Thomas, T., Thomas, G., McLendon, C., Sutton, T., & Mullan, M. (1996) · Nature · doi:10.1038/380168a0 · Cited by 703 · cited 3×
“Aβ has been identified in media and adventitia of small arteries and capillaries of cerebral and peripheral vessels earlier.(11,13,21) Investigators have proposed that vascular dysfunction is an early component of AD pathology.”
BackgroundPike, C. J., Walencewicz‐Wasserman, A. J., Kosmoski, J., Cribbs, D. H., Glabe, C. G., & Cotman, C. W. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64010253.x · Cited by 699 · cited 2×
“Aβ (25–35) exhibits a potent vasoconstrictor effect in rat skin microvasculature and elicits endothelial dysfunction.(8) Aβ (25–35) also induces interleukin 1β release from macrophages and microglia.”
Backgroundβ-Amyloid, Blood Vessels, and Brain Function
Smith, E. E., & Greenberg, S. M. (2009) · Stroke · doi:10.1161/strokeaha.108.536839 · Cited by 293
Threats to the Mind: Aging, Amyloid, and Hypertension
Iadecola, C., Park, L., & Capone, C. (2009) · Stroke · doi:10.1161/strokeaha.108.533638 · Cited by 207
Cited by
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease
Lee, D., Clark, E. D., Antonsdottir, I. M., & Porsteinsson, A. P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2195539 · Cited by 28
MicroRNA-Target Interaction Regulatory Network in Alzheimer’s Disease
Turk, A., Kunej, T., & Peterlin, B. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121275 · Cited by 20
Roeben, B., the TREND study team, Maetzler, W., Vanmechelen, E., Schulte, C., Heinzel, S., Stellos, K., Godau, J., Huber, H., Brockmann, K., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150575 · Cited by 19
Metadata
- Authors
- Haase, N., Herse, F., Spallek, B., Haase, H., Morano, I., Qadri, F., Szijártó, I. A., Rohm, I., Yilmaz, A., Warrington, J. P., Ryan, M. J., Gollasch, M., Müller, D. N., Dechend, R., & Wallukat, G.
- Venue
- Hypertension
- Published
- 2013-11
- Volume
- 62
- Issue
- 5
- Pages
- 966-972
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2147940316
- Cited by
- 36
- References
- 5
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amyloid-β Peptides Activate α 1 -Adrenergic Cardiovascular Receptors. https://app.cochat.ai/papers/10.1161/hypertensionaha.113.01348
- The paper
- Haase, N., Herse, F., Spallek, B., Haase, H., Morano, I., Qadri, F., Szijártó, I. A., Rohm, I., Yilmaz, A., Warrington, J. P., Ryan, M. J., Gollasch, M., Müller, D. N., Dechend, R., & Wallukat, G. (2013). Amyloid-β Peptides Activate α 1 -Adrenergic Cardiovascular Receptors. Hypertension. https://doi.org/10.1161/hypertensionaha.113.01348
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.